Pharmaco - Today Stories

Company Executives Honored for Notable Biopharmaceutical Industry Impact MORRISVILLE, N.C., May 16, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced PM360 has named Maria Fotiu, President, Sites and Patients, Syneos Health; Sayee Natarajan, CEO & Co-founder, RxDataScience (a Syneos Health company); and Greg Christie, Chief Product Officer, StudyKIK (a Syneos Health company), as recipients of its 9th Annual ELITE Awards. The PM360 ELITE Awards recognize individuals in 19 categories in the life sciences industry who exemplify the following traits: Exceptional Leaders, Innovators, Transformers, and Entrepreneurs (ELITE). Maria Fotiu is honored in the Strategists category for constantly leading her…

Collaboration will leverage Bicycle Therapeutic’s synthetic peptides for the discovery and development of multiple targeted radioconjugates of the company in oncology Advancing the use of bicycle peptides as a novel targeting approach in radiopharmaceuticals Bicycle Therapeutics to receive upfront payment of USD 45 million, and potential future development and commercial-based milestones, up to a total of USD 1.7 billion, plus tiered commercial royalties BERLIN & CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bayer and Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics by utilizing proprietary bicyclic peptides technology (Bicycle®), today announced that they have entered into a strategic collaboration agreeme…

– Acquisition of XinThera Provides Gilead with Precision Small Molecules Focused on PARP1 and MK2 Inhibitors – FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced the acquisition of all outstanding shares of XinThera, a privately held biotech company in San Diego. The acquisition complements Gilead’s existing clinical development priorities by adding additional pipeline assets for well-validated targets in oncology and inflammation. Through the acquisition, Gilead gains rights to a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases that could enter clinical trials later this year. Both programs have the potential to address multiple indications, offering broad development opportunities alone and in…

Proposed divestiture of BioPharma Solutions (BPS) further streamlines Baxter’s strategic focus and represents an important milestone in its ongoing business transformation Net proceeds planned to be redeployed for debt repayment in accordance with Baxter’s stated capital allocation priorities Establishes a diversified, standalone contract development and manufacturing organization (CDMO) platform enhancing healthcare worldwide DEERFIELD Ill. and BOSTON and NEW YORK - 2023-05-08 Baxter International Inc. (NYSE:BAX), a leading global medtech company, today announced that it has signed a definitive agreement to divest its BioPharma Solutions (“BPS”) business to Advent International (“Advent”), one of the largest and most experienced global private equity investors, and Warburg…

Global Bayer Co.Lab network of life science incubators established to accelerate innovation and foster collaborations within vibrant biotech ecosystems / U.S. flagship location opening in Cambridge, MA, encompasses state-of-the-art laboratories and collaborative working space designed specifically to support entrepreneurs focused on developing the next generation of cell and gene therapies / Bayer’s Co.Lab Cambridge co-located with the Bayer Research and Innovation Center (BRIC), BlueRock Therapeutics, and Leaps by Bayer, allowing for direct access to Bayer’s experts / Investment part of Bayer’s continued strategic investment in the U.S. Berlin / Boston-Cambridge, MA, USA, May 5, 2023 – Bayer AG yesterday announced the inauguration of its new life science incubator dubbe…

The Institute of Human Biology aims to better predict which drug candidates are safe and most effective in patients by evolving and increasing the use of human model systems. Human model systems are miniature living 'replicas' of human tissues and organs that also have the potential to reduce reliance on animal testing. The institute brings together scientists from academia and industry to lead the broad adoption of human model systems in pharmaceutical R&D as well as in clinical practice. Basel, 4 May 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of the Institute of Human Biology (IHB) focussing on advancing research in the field of human model systems such as organoids. Leveraging human model systems, the institute aims to accelerate drug discovery and develo…

Enhancing the research and production of drugs in Europe Major investment solidifies Germany’s and Europe’s position as a leading production hub for global medication supply Boehringer Ingelheim breaks ground to build a new Chemical Innovation Plant at its headquarters in Ingelheim, Germany. In the presence of German Chancellor Olaf Scholz and Rhineland-Palatinate Minister-President Malu Dreyer, the foundation stone for the major investment of 285 million EUR was laid today. Starting in 2026, this facility will develop manufacturing processes for active pharmaceutical ingredients and produce drugs for use in clinical trial phases. This step is crucial for Boehringer Ingelheim to rapidly advance new drug candidates from the company’s vast research pipeline to clinical trials and ultima…

Giovanni Caforio, MD, Bristol Myers Squibb Chairman and CEO, to Retire as CEO, Effective November 1, 2023; Will Continue as Executive Chairman of the Board Christopher Boerner, PhD, EVP, Chief Commercialization Officer, Appointed EVP, Chief Operating Officer, Effective Immediately; to Succeed Giovanni Caforio, MD, as CEO, Effective November 1, 2023 Adam Lenkowsky Appointed EVP, Chief Commercialization Officer, Effective Immediately NEW YORK--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that Giovanni Caforio, MD, Chairman of the Board and Chief Executive Officer, has decided to retire as Chief Executive Officer, effective November 1, 2023. Christopher Boerner, PhD, EVP, Chief Commercialization Officer, has been named EVP, Chief Operating Officer, effective immediat…

Investment of 350 million EUR in state-of-the-art research infrastructure is Boehringer Ingelheim’s largest single investment in Germany to date Boehringer Ingelheim strengthens innovation power and development of biopharmaceuticals, which account for approx. 50 percent of the company’s research pipeline New high-tech facility in Biberach offers attractive workplaces for more than 500 scientists Boehringer Ingelheim today inaugurated its state-of-the-art Biologicals Development Center (BDC) in Biberach an der Riß, Germany. The new high-tech facility underlines the company’s strong commitment to Germany and Europe as location for research and development (R&D) for the care of patients around the world. With the investment of 350 million EUR, Boehringer Ingelheim significantly enhan…

In addition to $3.7 billion investment in Boone County, Lilly will commit $15 million to Ivy Tech to foster a diverse talent pipeline for high-tech manufacturing jobs INDIANAPOLIS, April 17, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that it will invest an additional $1.6 billion and add another 200 new jobs at its two new manufacturing sites within LEAP Innovation Park in Boone County, bringing the company's total commitment to $3.7 billion and up to 700 new jobs. The company also today committed $15 million over five years to the Ivy Tech Foundation to fund up to 1,000 scholarships for individuals interested in pursuing careers in pharmaceutical manufacturing. Lilly's commitments within LEAP Innovation Park represent the largest manufacturing investment at a s…

Acquisition further strengthens specialty medicines and respiratory pipeline with camlipixant, a highly selective P2X3 antagonist and potential best-in-class treatment for refractory chronic cough Currently in phase III clinical development with anticipated regulatory approval and launch in 2026 Accretive to adjusted EPS from 2027 with significant sales potential through 2031 GSK plc (LSE/NYSE: GSK) and BELLUS Health Inc. (TSX/NASDAQ: BLU) today announced that they have entered into an agreement under which GSK will acquire BELLUS, a Canada-based, late-stage biopharmaceutical company working to better the lives of patients suffering from refractory chronic cough (RCC) for US$14.75 per share of common stock in cash representing an approximate total equity value of US$2.0 billion (£1.6 bil…

PRA023 is a novel, late-stage candidate for ulcerative colitis and Crohn’s disease and other autoimmune conditions Prometheus Biosciences’ comprehensive data set enables target discovery and precision medicine approach in inflammation and immunology RAHWAY, N.J. & SAN DIEGO--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Prometheus Biosciences, Inc. (“Prometheus”) (Nasdaq: RXDX) today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, has agreed to acquire Prometheus for $200.00 per share in cash for a total equity value of approximately $10.8 billion. “At Merck, we are committed to delivering on our purpose to save and improve lives and continue to identify and secure opportuni…

Partnership will leverage Aspect’s proprietary bioprinting technology and Novo Nordisk’s expertise and technology in stem cell differentiation and cell therapy development and manufacturing. Aspect to receive 75 million US dollars in initial payments and up to 650 million dollars in future milestone payments per product arising from the collaboration, plus tiered royalties. Vancouver, BC, Canada and Bagsværd, Denmark, 12 April 2023 – Aspect Biosystems and Novo Nordisk A/S today announced a collaboration, development, and licence agreement to develop bioprinted tissue therapeutics designed to replace, repair, or supplement biological functions inside the body with the aim of delivering a new class of truly disease-modifying treatments for diabetes and obesity. The collaboration will lever…

RAHWAY, N.J.‐‐(3BL MEDIA)‐‐Merck (NYSE: MRK), known as MSD outside of the United States and Canada, has earned a place on the Fortune 100 Best Companies to Work For list for the second time in the past three years. The company also made the list in 2021. “Our talented, diverse team is foundational to our ability to deliver on our purpose of saving and improving lives around the world,” said Steven C. Mizell, executive vice president and chief human resources officer, Merck. “We are honored by this significant recognition, which is reflective of our vibrant and inclusive culture, where employees feel seen, heard, valued and set up for continued success.” This year’s Best Companies to Work For list is based on the feedback of more than half a million U.S. employees, who responded to a nation…

Company Recognized for Positive Vaccine Expertise Contributions MORRISVILLE, N.C., April 05, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced it has been awarded the Vaccine Industry Excellence Award for Best Contract Research Organization (CRO). Presented at the 2023 World Vaccine Congress in Washington, D.C., the award recognizes the vaccine industry’s most outstanding efforts, accomplishments and positive contributions of companies and individuals. Syneos Health has an extensive range of industry-leading expertise in bacteriology, virology, mycology, and associated diseases and syndromes. In the past five years, the Company’s Catalyst Vaccine Network sites have conducted more than 700 vaccine stud…

RAHWAY, N.J.-–(3BL MEDIA)-– Merck (NYSE: MRK), known as MSD outside of the United States and Canada, has been named one of Barron’s 100 Most Sustainable U.S. Companies for the third consecutive year, ranking No. 1 in the pharmaceutical industry and advancing 38 spots in the overall rankings from last year—from No. 67 overall in 2022 to No. 29 overall in 2023.    “At Merck, we are committed to operating responsibly and moving with urgency to deliver value for patients, society and all of our stakeholders,” said Carmen Villar, vice president of Social Business Innovation for Merck. “We are pleased to see the impact of our work being recognized, and we will continue to make strides toward building a healthier, safer and more sustainable world.” Earlier this year, Merck was also recognized as…

Partnership will distribute screening kits to communities at higher risk of colon cancer BURLINGTON, N.C., April 3, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, is partnering with the Conference of National Black Churches (CNBC) to address health equity gaps in colorectal cancer screening. To raise awareness and provide expanded access to colorectal cancer screening tests, the Conference of National Black Churches will distribute over 3,000 colorectal screening test kits across several urban and rural locations including Atlanta, Dallas, Memphis, Washington D.C., New Haven, Los Angeles and Richmond. Colorectal cancer, which is the third most deadly type of cancer in the U.S., has a disproportionate impact on the Black community, according to the American…

Support to include dedicated educational website, science advisory panel, patient video series and strategic alliance across sleep patient advocacy organizations Research shows that sleep disorders are associated with increased risks of cardiovascular comorbidities, including those with narcolepsy being two- to three-times more likely to have a stroke or heart attack than people without narcolepsy DUBLIN, March 30, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced an expansion of its support of the American Heart Association (Association) to provide the sleep disorder community an in-depth understanding of the cardiovascular risks associated with these debilitating disorders. Through this initiative, the Association aims to help people living with sleep disorde…

Program Drives Digital and Omnichannel Engagement for Medical Science Liaison Teams & Medical Conferences MORRISVILLE, N.C., March 27, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq: SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced the launch of Medical Affairs Digital Amplifier, a program designed to drive smarter and more effective scientific exchange. This integrated program seeks to ensure customers, and the clinicians they serve, have access to the latest education to optimize patient outcomes. The development of this unique digital asset underscores Syneos Health’s continued focus on Medical Affairs, an increasingly critical component of successful clinical development. Fueled by the Company’s advanced digital engagement capabilities an…

GRANT FROM THE BILL & MELINDA GATES FOUNDATION SUPPORTS EVOTEC’S EFFORTS TO DISCOVER AND DEVELOP DRUG CANDIDATES FOR A UNIVERSAL, SHORTER, SAFER AND SIMPLER TUBERCULOSIS DRUG REGIMEN AS ONE OF ITS PROGRAMMES CONTRIBUTING TO THE UN SUSTAINABLE DEVELOPMENT GOAL 3 “WORLD TUBERCULOSIS DAY”, 24 MARCH RAISES PUBLIC AWARENESS ABOUT DEVASTATING HEALTH, SOCIAL AND ECONOMIC CONSEQUENCES OF THE TUBERCULOSIS EPIDEMIC Hamburg, Germany, 24 March 2023:Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company has received a US$ 6.6 m grant from The Bill & Melinda Gates Foundation for drug discovery in tuberculosis (“TB”). The grant is the second award from the foundation to Evotec supporting TB drug discovery, and allows the Company…